Clinical trials: Lipodystrophy
Lipodystrophy, Diabetes
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
Background: Generalized lipodystrophy can cause high blood fat levels and resistance to insulin. This can lead to health problems including diabetes.
- Conditions
- Lipodystrophy, Diabetes, Hyperlipidemia
- Trial name
- NCT02262832
- Testing
- Metreleptin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Generalized Lipodystrophy
Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy
This study is researching a new drug called mibavademab (called "study drug"). The study involves participants with a condition called Generalized Lipodystrophy (GLD).
- Trial name
- LAGO (NCT07220785)
- Testing
- Mibavademab
- Where
- 9 sites in United States, Brazil and 1 more
- Volunteers
- 28 people
- Sponsor
- Regeneron Pharmaceuticals
Nephrotic Syndrome, Lipodystrophy
Effects of Meal Macronutrients on Postprandial Lipids
Background: Abnormal fats in the blood can lead to many problems, including heart disease. Researchers want to learn more about how eating meals with different levels of nutrients affects fats in the blood.
- Conditions
- Nephrotic Syndrome, Lipodystrophy, Metabolic Syndrome, Healthy Volunteer
- Trial name
- NCT07313787
- Testing
- High carb then high fat breakfast, High fat then high carb breakfast
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes, Lipodystrophy
Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
Background: Partial lipodystrophy can cause high blood fat levels and resistance to insulin. This can lead to health problems including diabetes.
- Conditions
- Diabetes, Lipodystrophy, Hyperlipidemia
- Trial name
- NCT02262806
- Testing
- Metreleptin
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Deformity; Skin, Fat Redistribution
Safety and Efficacy of Deoxycholate Treatment of Small Fatty Deformities ( SFD)
The purpose of this study is to evaluate the efficacy and safety of deoxycholate for the treatment of lipocytic ("fatty") deformities of the trunk and lower extremities; this includes areas such as cellulite or body contour…
- Conditions
- Deformity; Skin, Fat Redistribution, Lipodystrophy
- Trial name
- SFD (NCT07880301)
- Testing
- Kybella
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- The Maas Clinic
Lipodystrophy, Dunnigan Syndrome
Impact of Lipodystrophy on the Inflammatory State of Non-diabetic Dunnigan Reunion Island Subjects
Few data and small numbers affect the inflammatory profile of Dunnigan patients. The levels of certain pro-inflammatory biomarkers would be found higher in these subjects compared to control individuals.
- Trial name
- LIPOKINES (NCT06107439)
- Testing
- Bood and urine sampling
- Where
- Reunion
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Lipodystrophy Congenital Generalized, Lipodystrophy, Familial Partial
Sexual Quality of Life in Female Patients With Lipodystrophy Syndromes or Turner's Syndrome: a Case-control Study
Turner syndrome (TS) and congenital lipodystrophy syndromes (LS) are rare conditions with major consequences on cardiometabolic health, fertility, and body morphology.
- Conditions
- Lipodystrophy Congenital Generalized, Lipodystrophy, Familial Partial, Turner Syndrome
- Trial name
- LIPTURN (NCT07799012)
- Where
- France
- Volunteers
- 1,416 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Expanded Access for Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
This is an expanded access designed to provide metreleptin for the treatment of diabetes mellitus and/or hypertriglyceridemia associated with lipodystrophy.
- Trial name
- NCT00677313
- Testing
- metreleptin
- Sponsor
- Bristol-Myers Squibb
Lipodystrophy
Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy
Background: Lipodystrophy is a health problem in which the body does not have enough fat tissue. People with lipodystrophy may not make enough of the hormone leptin. Leptin regulates hunger. Low leptin levels trigger hunger.
- Trial name
- NCT05419037
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Insulin Receptor Mutation, Partial Lipodystrophy
Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance
Background: Lipodystrophy (LD) syndromes are a group of rare disorders that affect how a person s body can store and use fat tissue. Many people with LDs become severely insulin resistant.
- Trial name
- NCT05470504
- Testing
- Pegvisomant
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Lipodystrophy
Feasibility of Adipose Tissue Triglyceride (TG) Labelling in Familial Partial Lipodystrophy (FPLD)
Background: People with familial partial lipodystrophy (FPLD) do not store fat in the body normally. This can lead to serious illnesses such as diabetes and heart disease.
- Trial name
- NCT05996536
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Polycystic Ovary Syndrome, Familial Partial Lipodystrophy
Identification of Women With Severe Insulin Resistant Syndromes of Genetic Origin Among Patients With "Classic" Polycystic Ovary Syndrome (PCOS)
Diagnostic case-control study (1 case for 2 controls). Inclusion of patients with severe insulin resistance syndrome of genetic origin, then inclusion of controls: patients examined for PCOS in day hospital with matching age (+/…
- Conditions
- Polycystic Ovary Syndrome, Familial Partial Lipodystrophy, LMNA (LaMin Nuclear A) Related Disorders
- Trial name
- ANDROLIPO (NCT07412028)
- Testing
- Genetic analysis, Biological analysis, imaging test
- Where
- France
- Volunteers
- 81 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lipodystrophy
Assess the Possibility of Diagnosing Diabetes and Rediabetes Following Oral Induced Hyperglycemia in Patients With Dunnigan's Partial Familial Lipodystrophy by Replacing 75 g of Glucose With a Standardized Carbohydrate Breakfast and Continuous Interstitial Monitoring Glucose)
Dunnigan's syndrome is a partial familial lipodystrophy due to a mutation in the Lamine A LMNA gene. This very rare syndrome is 20 times more common in Réunion compared to the rest of Europe with several families suffering from a…
- Trial name
- HGPO-DUN (NCT05789251)
- Testing
- Standardized breakfast
- Where
- Reunion
- Volunteers
- 54 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Generalized Lipodystrophy
A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
This study is researching an experimental drug called mibavademab. The study is focused on participants with GLD who have been on metreleptin treatment for at least 6 months with no change in dose for the last 3 months.
- Trial name
- NCT06548100
- Testing
- mibavademab
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Regeneron Pharmaceuticals
Generalized Lipodystrophy
Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy
This is an open-label, Phase 3b study to evaluate effectiveness, safety and pharmacokinetic parameters of metreleptin in patients under 6 years of age with generalised lipodystrophy and associated diabetes mellitus and/or…
- Trial name
- NCT06502990
- Testing
- Metreleptin
- Where
- 12 sites in Belgium, France and 2 more
- Volunteers
- 1 people
- Sponsor
- Amryt Pharma
Generalised Lipodystrophy, Partial Lipodystrophy
MEASuRE: Metreleptin Effectiveness And Safety Registry
The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA.
- Trial name
- MEASuRE (NCT02325674)
- Testing
- Metreleptin
- Where
- 28 sites in United States, France and 3 more
- Volunteers
- 100 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Familial Partial Lipodystrophy
Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
This Phase 3 study is an Open Label Extension of the APG-20 Study To Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with Partial Lipodystrophy
- Trial name
- NCT06679270
- Testing
- Metreleptin
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Cellulite, Gynoid Lipodystrophy
Quantitative Assessment of the Efficacy of Alidya
This study evaluated the efficacy of ALIDYA, a Class III medical device used in needle mesotherapy, for the treatment of cellulite (gynoid lipodystrophy) in women.
- Trial name
- NCT07675356
- Testing
- ALIDYA
- Where
- 2 sites in Poland
- Volunteers
- 30 people
- Sponsor
- Medical University of Silesia
Generalized Lipodystrophy
Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy
The primary objectives of the study are to estimate the effects of REGN4461 on glycemic parameters in the subset of patients with elevated baseline hemoglobin A1c levels (HbA1c ≥7%) and to estimate the effects of REGN4461 on…
- Trial name
- NCT04159415
- Testing
- Low-Dose REGN4461, High-dose REGN4461
- Where
- 8 sites in United States, Peru and 2 more
- Volunteers
- 16 people
- Sponsor
- Regeneron Pharmaceuticals
Partial Lipodystrophy
Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL
This is a Phase III, double-blind, placebo-controlled, safety and efficacy study of daily SC metreleptin in subjects with Partial Lipodystrophy.
- Trial name
- METRE-PL (NCT05164341)
- Testing
- metreleptin
- Where
- 31 sites in United States, Belgium and 7 more
- Volunteers
- 69 people
- Sponsor
- Chiesi Farmaceutici S.p.A.